MedTrace Logo

PET Study of Breast Cancer Patients Using [68Ga]ABY-025

NCT01858116 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2015-01-13

No results posted yet for this study

Summary

The study will evaluate \[68Ga\]ABY-025 for PET imaging of HER2 expression in subjects with HER2-positive or HER2-negative breast cancer.

Conditions

Interventions

DRUG

[68Ga]ABY-025

Intravenous injection followed by PET imaging

Sponsors & Collaborators

  • Swedish Cancer Society

    collaborator OTHER

  • Affibody

    collaborator INDUSTRY

  • Biomedical Radiation Sciences

    lead OTHER

Principal Investigators

  • Henrik Lindman, MD, PhD · Uppsala University Hospital, Department of Oncology

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01858116 on ClinicalTrials.gov